About The Study: In this cohort study, glucagon-like peptide-1 receptor agonist (GLP-1RA) use was associated with reduced risk of developing nonexudative age-related macular degeneration (AMD) but was not associated with progression to exudative AMD among individuals with nonexudative AMD. These findings may inform future randomized trials evaluating the ocular effects of GLP-1RAs in nondiabetic populations.
Corresponding Author: To contact the corresponding author, Benjamin K. Young, MD, MS, email youngbe@ohsu.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaophthalmol.2025.3821)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2025.3821?guestAccessKey=17550413-8ea9-439f-b82f-ae4cae7e437f&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102325
JAMA Ophthalmology